[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586182":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":42,"responsibleParty":62,"collaborators":17,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":17,"enrollmentInfo":75,"targetDuration":17,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":45,"whyStopped":17,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University of Ulm","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Atropine Infusion","EXPERIMENTAL","5 µg x kg fat free mass-1 x h-1",[13],"Other: Oral glucose tolerance test with double-tracer dilution and atropine infusion",{"label":15,"type":16,"description":17,"interventionNames":18},"Saline infusion","PLACEBO_COMPARATOR",null,[19],"Other: Oral glucose tolerance test with double-tracer dilution and saline infusion (placebo)",[21,25],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":17},"Oral glucose tolerance test with double-tracer dilution and atropine infusion","Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \\[6,6-2H\\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Atropine infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \\[U-13C6\\]-glucose.",[9],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":17},"Oral glucose tolerance test with double-tracer dilution and saline infusion (placebo)","Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \\[6,6-2H\\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Saline infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \\[U-13C6\\]-glucose.",[15],[30],{"name":31,"affiliation":32,"role":33},"Martin Heni, MD","Ulm University Hopital","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":17,"email":38},"CONTACT","+4973150044505","martin.heni@uniklinik-ulm.de",{"name":40,"role":36,"phone":17,"phoneExt":17,"email":41},"Andrea Geissler","andrea.geissler@uniklinik-ulm.de",[43],{"facility":44,"status":45,"city":46,"state":17,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Ulm University Hospital","RECRUITING","Ulm","89081","Germany","DE",{"type":51,"coordinates":52},"Point",[53,54],9.99155,48.39841,{"lat":54,"lon":53},[57,61],{"name":58,"role":36,"phone":59,"phoneExt":17,"email":60},"Sabrina Wangler","+4973150044782","sabrina.wangler@uniklinik-ulm.de",{"name":40,"role":36,"phone":17,"phoneExt":17,"email":41},{"type":33,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Martin Heni","Prof. Dr. med. Martin Heni","100586182","understanding-individual-variability-in-neuronal-signal-transmission-to-target-organs-in-health-and-disease-100586182",false,"NCT06912048","Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease","CPB_Atropine","Inclusion Criteria:\n\n* Age: at least 18\n* BMI: 20 - 24.9 kg\u002Fm2 (for the healthy groups) or more than 28 kg\u002Fm2 (for the overweight groups)\n* For women: Hormonal contraception with a single-phase preparation (e.g. Nuvaring)\n* Understanding and voluntarily signing an informed consent form prior to study-related examinations\n\nExclusion Criteria:\n\n* Drug and\u002For alcohol abuse\n* smoking\n* Taking medication that affects blood sugar or addresses the central and\u002For autonomic nervous system (e.g. anti-epileptic drugs, beta blockers, dopamine agonists, antidepressants). Taking antihistamines.\n* Pre-existing cardiac conditions\n* Neurological pre-existing conditions\n* Known cardiac arrhythmia\n* Known allergies to ingredients, e.g. paracetamol and atropine\n* Known narrow-angle glaucoma\n* Known hyperthyroidism\n* Known diseases of the urinary tract or prostate\n* Pregnancy or breastfeeding\n* At screening: Hb \\\u003C 12 g\u002Fdl for women and Hb \\\u003C 14 g\u002Fdl for men\n* No consent to be informed about incidentally discovered pathological findings\n* Any (clinical) condition which, in the opinion of the physician, could jeopardize the safety of the\n* or would jeopardize the scientific success.\n* Liver dysfunction\n* Renal insufficiency",true,"ALL","18 Years",{"count":76,"type":77},52,"ESTIMATED","INTERVENTIONAL",[80],"NA","The goal of this clinical trial is to evaluate the influence of parasympathetic transmission from the brain to different metabolic organs. This transmission can be blocked with the muscarinic antagonist atropine.\n\nParticipants will undergo an oral glucose tolerance test combined with a double tracer dilution technique either with atropine infusion or placebo.\n\nHealthy individuals and high-risk individuals will be compared to identify possible changes in signaling in high-risk groups. In addition, men and women will be included to take into account possible sex differences.",[83],"Autonomic Function",[85,86,87,88,89,90,91,92,93],"parasympathetic transmission","autonomic nervous system","brain periphery crosstalk","metabolism","insulin sensitivity","insulin secretion","endogenous glucose production","sex differences","high risk population","2025-07-04",{"date":96,"type":97},"2025-07-10","ACTUAL",{"date":99,"type":97},"2025-05-14",{"date":101,"type":77},"2027-05",{"name":5,"class":6},1]